Celltrion is expanding its collaboration with the Seoul Bio Hub to enhance its bio startup discovery and partnership program. The company has selected four startups with next-generation technologies, including AI-based protein antibody development, organoids, disease modeling, and oral delivery formulations, for its fourth phase of the Open Innovation Program. This initiative is expected to contribute to the ongoing growth of the domestic biotech ecosystem.
On June 10, Celltrion announced the final selection of four companies for the fourth phase of the 2026 Seoul Bio Hub-Celltrion Open Innovation Program.
The selected companies include: 1) AINB, which specializes in AI-based protein antibody development; 2) EnbioCell, which focuses on a GLP-1 derivative oral delivery formulation platform based on ChargeSmed; 3) Imita Science, known for its biomimetic tissue-based disease modeling and drug evaluation technology; and 4) Podotherapeutics, which offers a precision medicine platform based on patient-derived organoids (PDO).
These companies were chosen after a thorough evaluation by a review panel that included external technology assessors. The four startups will receive tailored support at various stages of growth, including joint research and commercialization opportunities, technology advancement, and mentoring from Celltrion.
A Celltrion representative stated, "This program aims to discover biotech and medical startups with innovative technologies that can align with Celltrion's research and development needs, and to support technology advancement and growth through collaboration with the Seoul Bio Hub." The company plans to assist the growth of promising firms and expand the collaborative foundation of the domestic biotech ecosystem.
Since 2020, Celltrion has participated as a private operator in the Incheon Startup Park development project. Additionally, it is involved in the K-Bio Lab Hub construction project, leading efforts to discover and nurture promising companies through its open innovation strategy.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.